ClinicalTrials.gov reports pharmacokinetic results for apremilast study

A completed Phase 1 study in 28 healthy Korean men reports pharmacokinetic measurements for single and repeated doses of apremilast.

By LIVE AGAIN Editorial Desk Published 14 Sept 2026 1 min read

Editorial illustration of medical device and medicine safety review — LIVE AGAIN / AI-generated editorial illustration · AI-generated

ClinicalTrials.gov has posted results from NCT02802735, a completed Phase 1 pharmacokinetic study of apremilast in healthy adult Korean men.

The registry reports 28 enrolled participants. In one study part, participants received single doses of 20, 30 and 40 milligrams across treatment periods; another part compared 30 milligrams twice daily with placebo over 14 days. The posted tables report measured plasma concentrations and related pharmacokinetic outcomes.

Because this was a small early-phase study in healthy volunteers, its results do not establish clinical effectiveness or safety for patients with a disease. The registry data should not be read as a treatment recommendation.

Research & Studies

ClinicalTrials.gov posts results from montelukast study in smokers with asthma

ClinicalTrials.gov has posted results from a completed Phase 4 study evaluating treatment approaches in smokers with asthma.

14 Sept 20261 min read

Read article

Editorial illustration of kidney transplant research and clinical outcome monitoring

Research & Studies

Registry Results Report Dapagliflozin Findings in Kidney Transplant Recipients

Registry results from the INFINITI study show numerical differences between dapagliflozin and placebo after 12 weeks, but the registry tables provide no comparative p-values or confidence intervals.

8 Sept 20261 min read

Read article